Evolent Health (EVH) shares soared 9.50% in pre-market trading on Friday, building on the previous day's 10.33% gain. The healthcare solutions provider continues to ride the wave of enthusiasm following its better-than-expected third-quarter results and a series of positive developments announced on Thursday.

The company reported Q3 revenue of $479.53 million, surpassing analyst expectations of $467.50 million. Evolent also revealed over $500 million in new annualized revenue for 2026 from two new agreements, contributing to a total of thirteen new contracts signed this year. This significant boost to future revenue streams has clearly excited investors.

Adding to the optimism, Evolent provided a strong outlook for both the near and long term. The company projects full-year 2025 revenue to reach $1.87 billion to $1.88 billion, with an impressive preliminary 2026 revenue forecast of $2.5 billion. This robust growth potential, coupled with innovative partnerships like the one announced with American Oncology Network aimed at streamlining cancer care, has fueled investor confidence in Evolent Health's future prospects.